CA 19-9: Not a magic marker for pancreatic cancer

Southern Medical Journal

Volumn 99, Issue 3, 2006, Pages 205-

  Daram, Sumanth R ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Wheaton Franciscan Healthcare St Joseph's Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CA 19-9 ANTIGEN;

ACUTE HEPATITIS; AGED; CANCER DIAGNOSIS; CANCER SCREENING; CASE REPORT; CHRONIC LIVER DISEASE; COMMON BILE DUCT STONE; CORRELATION ANALYSIS; DIAGNOSTIC IMAGING; DISEASE MARKER; EDITORIAL; HUMAN; LIVER FAILURE; LIVER FUNCTION TEST; MALE; OBSTRUCTIVE JAUNDICE; PANCREAS CANCER; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; AGED; CA-19-9 ANTIGEN; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33645098017     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.smj.0000204525.62861.85     Document Type: Editorial

References (9)

1. Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somat Cell Mol Genet 1979;5:957-971.
2. Duffy MJ. CA 19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem 1998;35:364-370.
3. Sakahara H, Endo K, Nakajima K, et al. Serum CA 19-9 concentrations and computed tomography findings in patients with pancreatic carcinoma. Cancer 1986;57:1324-1326.
4. Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker CA 19-9 in acute cholangitis. Dig Dis Sci 1988;33:1223-1225.
5. Kim J, Lee K, Lee J, et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004;19:182-186.
6. Lowe D, Lee J, Schade R, et al. Patient with markedly elevated CA 19-9 not associated with malignancy. South Med J 2006;99:306-308.
7. Maestranzi S, Przemioslo R, Mitchell H, et al. The effect of benign and malignant liver disease on the tumour markers CA 19-9 and CEA. Ann Clin Biochem 1998;35:99-103.
8. Mann DV, Edwards R, Ho S, et al. Elevated tumour marker CA 19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000;26:474-479.
9. Shimomura C, Eguchi K, Kawakami A, et al. Elevation of a tumor-associated antigen CA 19-9 in patients with rheumatic diseases. J Rheumatol 1989;16:1410-1415.